Protocol Ledger

NCT05850520 · Phase III · COMPLETED

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blo

Interventional Phase III clinical trial protocol NCT05850520 sponsored by Bayer in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-15 Enrollment: 892 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05850520
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)892 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05850520
Protocol FieldVerified Registry Value
NCT IdentifierNCT05850520
Consolidated Lead SponsorBayer
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment892 participants (ACTUAL)
Registered Start Date2023-05-15
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI